Vogenx Announces Closing of Initial Public Offering

Rhea-AI Summary

Vogenx (NASDAQ:VOGX), a clinical-stage biopharmaceutical company targeting metabolic disorders such as post-bariatric hypoglycemia (PBH) and gastroparesis, closed its initial public offering of 6,250,000 common shares at $13.00 per share, generating gross proceeds of approximately $81.3 million before fees and expenses.

Vogenx’s stock began trading on the Nasdaq Capital Market on August 12, 2026 under the ticker VOGX. The company granted underwriters a 45-day option to buy up to an additional 937,500 shares. Vogenx’s lead candidate mizagliflozin is being developed for PBH, gastroparesis, and GIP-dependent Cushing's Syndrome.

Positive

• IPO gross proceeds of approximately $81.3 million before fees
• All 6,250,000 shares sold by Vogenx, strengthening its cash position
• Shares listed on the Nasdaq Capital Market under ticker VOGX
• Lead candidate mizagliflozin in development for multiple metabolic indications

Negative

• Newly issued 6,250,000 shares dilute pre-IPO shareholders
• Underwriters’ 45-day option for up to 937,500 additional shares could add further dilution if exercised

News Explained

The closed IPO increases total shares and dilutes existing percentage ownership; reported proceeds are gross and reduced by offering costs.

The IPO is closed: Vogenx was the seller of 6,250,000 shares, so the offering increases the total share count and reduces existing holders’ percentage ownership.

The reported $81.3 million is gross proceeds, not the amount retained after underwriting discounts, commissions, and other offering expenses; no net proceeds figure is provided.

The additional 937,500 shares remain a 45-day underwriters’ option rather than part of the closed 6,250,000-share sale.

Key Figures

Shares offered: 6,250,000 shares Offering price: $13.00 per share Gross proceeds: approximately $81.3 million +3 more

6 metrics

Shares offered 6,250,000 shares Initial public offering

Offering price $13.00 per share Initial public offering

Gross proceeds approximately $81.3 million Before underwriting discounts, commissions, and other offering expenses

Underwriter option 937,500 shares 45-day option at the public offering price, less discounts and commissions

Nasdaq trading commencement August 12, 2026 Common stock began trading under VOGX

Registration effectiveness August 11, 2026 Form S-1 registration statement declared effective

Key Terms

initial public offering, underwriting discounts and commissions, form s-1, small molecule

4 terms

initial public offering financial

"announced the closing of its initial public offering of 6,250,000 shares"

An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

underwriting discounts and commissions financial

"before deducting underwriting discounts and commissions and other offering expenses"

Underwriting discounts and commissions are fees paid to financial institutions that help sell new securities to investors. They act like a commission for their role in connecting companies with buyers, often reducing the amount of money the issuing company raises. For investors, understanding these costs helps gauge how much of their investment is going toward the actual securities versus fees paid to middlemen.

form s-1 regulatory

"A registration statement on Form S-1 (File No. 333-297487)"

A Form S-1 is the registration filing a company submits to the U.S. Securities and Exchange Commission when it plans to offer stock to the public, most commonly for an initial public offering. Think of it as the company’s full disclosure packet or blueprint: it contains audited financials, business description, management background, risk factors and details of the offering, giving investors the information needed to judge the company’s financial health and potential risks before buying shares.

small molecule technical

"an orally administered, minimally absorbed small molecule drug candidate"

A small molecule is a low-weight chemical compound that can enter cells easily and interact with specific proteins or biological pathways to change how they work, much like a small key fitting into a lock. Investors care because small molecules are a common and often faster route to develop medicines, can be manufactured at scale, and may offer clearer regulatory and commercial paths compared with larger biologic therapies, affecting potential costs, timelines and returns.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RALEIGH, NC / ACCESS Newswire / August 13, 2026 / Vogenx, Inc. (NASDAQ:VOGX) ("Vogenx"), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia (PBH) and gastroparesis, today announced the closing of its initial public offering of 6,250,000 shares of its common stock at a public offering price of $13.00 per share. All of the shares were offered by Vogenx. The gross proceeds to Vogenx from the offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately $81.3 million.

Vogenx's common stock began trading on the Nasdaq Capital Market on August 12, 2026 under the ticker symbol "VOGX."

In addition, Vogenx has granted the underwriters a 45-day option to purchase up to an additional 937,500 shares of common stock at the public offering price, less underwriting discounts and commissions.

Jones acted as sole book-running manager for the offering.

A registration statement on Form S-1 (File No. 333-297487), as amended, relating to the offering was filed with the U.S. Securities and Exchange Commission (the "SEC") and was declared effective on August 11, 2026. The offering was made only by means of a prospectus forming part of the registration statement relating to these securities. Copies of the final prospectus relating to the offering may be obtained through the SEC's website at www.sec.gov, or from: JonesTrading Institutional Services LLC, Attention: Capital Markets, 325 Hudson Street, 6th Floor, New York, NY 10013, or by email at compliance@jonestrading.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Vogenx

Vogenx is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including PBH and gastroparesis. Vogenx's lead product candidate, mizagliflozin, is an orally administered, minimally absorbed small molecule drug candidate in development for the treatment of PBH, gastroparesis, and GIP-dependent Cushing's Syndrome. Vogenx licensed worldwide rights to mizagliflozin, excluding Japan, Korea and Taiwan, from Kissei Pharmaceutical in 2021.

Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include, but are not limited to, statements relating to the anticipated use of proceeds from the initial public offering. The words, without limitation, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, the factors discussed in the "Risk Factors" section of the prospectus that forms a part of the registration statement, as amended, filed with the Securities and Exchange Commission related to the initial public offering. Any forward-looking statements contained in this press release are based on the current expectations of Vogenx's management team and speak only as of the date hereof, and Vogenx specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact

Harrison Seidner, PhD
WaterSeid Partners, Inc.
(516) 236-5988
harrison@waterseid.com

SOURCE: Vogenx, Inc.

View the original press release on ACCESS Newswire

FAQ

What were the key terms of the Vogenx (NASDAQ:VOGX) IPO that closed on August 13, 2026?

The Vogenx IPO sold 6,250,000 common shares at $13.00 each, raising about $81.3 million in gross proceeds. According to Vogenx, all shares were offered by the company, before underwriting discounts, commissions, and other offering expenses.

How much capital did Vogenx (VOGX) raise from its initial public offering?

Vogenx raised approximately $81.3 million in gross proceeds from its IPO. According to Vogenx, this figure is before deducting underwriting discounts, commissions, and other offering expenses associated with the sale of 6,250,000 shares at $13.00 per share.

When did Vogenx (VOGX) begin trading on the Nasdaq Capital Market?

Vogenx began trading on the Nasdaq Capital Market on August 12, 2026 under the ticker symbol VOGX. According to Vogenx, the IPO pricing and subsequent closing followed effectiveness of its Form S-1 registration statement on August 11, 2026.

Does the Vogenx (VOGX) IPO include an over-allotment option for underwriters?

Yes, underwriters received a 45-day option to purchase up to 937,500 additional shares at the IPO price, excluding discounts and commissions. According to Vogenx, this option is in addition to the 6,250,000 shares sold in the base offering.

What therapeutic areas is Vogenx (VOGX) targeting with its lead drug candidate mizagliflozin?

Vogenx is developing mizagliflozin for post-bariatric hypoglycemia, gastroparesis, and GIP-dependent Cushing's Syndrome. According to Vogenx, mizagliflozin is an orally administered, minimally absorbed small molecule targeting serious diseases linked to metabolic dysfunctions, with worldwide rights licensed from Kissei Pharmaceutical excluding Japan, Korea, and Taiwan.

What type of company is Vogenx (VOGX) following its IPO?

Vogenx is a clinical-stage biopharmaceutical company focused on novel therapeutics for serious metabolic diseases. According to Vogenx, its research centers on conditions such as post-bariatric hypoglycemia and gastroparesis, with mizagliflozin as its lead orally administered drug candidate across several metabolic indications.